Patents Assigned to Case Western Reserve
  • Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in DDX39B (RS2523506) and IL7R (RS6897932)
    Patent number: 12203138
    Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: January 21, 2025
    Assignees: Board of Regents, The University of Texas System, Duke University, Case Western Reserve, The Regents of the University of California
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B. S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko
  • Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in DDX39B (RS2523506) and IL7R (RS6897932)
    Patent number: 10961581
    Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: March 30, 2021
    Assignees: Board of Regents, The University of Texas System, Duke University, Case Western Reserve, The Regents of the University of California
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B. S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko